Kabutaro's purchase
Purchase date: 2026-01-06
Amount: JPY 80,000
Quantity: 2 shares
Price per share: JPY 40,000
Type: Common stock
Angel tax scheme: Eligible (Type B)
Basic information
Company: atDose Inc.
Field: Medical devices (drug delivery)
Listing status: Unlisted (plans an IPO in the year to August 2030)
Links
FUNDINNO project page (Japanese)
This page is a translation of the Japanese page, which is updated first: Japanese version
Company profile
Founded: September 2017
Head office: Yokohama, Kanagawa
Representative: Hidetaka Nakamura, CEO
Capital: JPY 82,500,000 (as of October 14, 2025)
Sales: About JPY 1 million (year to August 2025), about JPY 6 million (year to August 2026, plan)
Offering terms
Target amount: JPY 12 million
Maximum amount: JPY 99.92 million
Shareholder benefits
None
Business
atDose uses electro-osmotic flow, which pushes liquid with electricity, to build devices that deliver very small amounts of a drug to a target spot in the body at a steady rate. It aims for cancer treatment with fewer side effects. This was its second fundraising on FUNDINNO, after 2024.
・atDose Core: An electric syringe that delivers even thick drugs accurately in tiny amounts. Patented
・Eye suction device: Launch planned for 2026
・India: Starts with complications of diabetes, aiming to bring the business back to Japan later
Notes
FUNDINNO investments are unlisted shares, so they cannot be sold until the company lists or is acquired. Company details and plans are based on the FUNDINNO project page and the company's announcements.
Current status
Listing / M&A: –
Valuation: –
Related pages: IPO / Trade History / Annual Results